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Background: Cognitive behavioural therapy is an effective treatment for depression. However, one third of the
patients do not respond satisfactorily, and relapse rates of around 30 % within the first post-treatment year were
reported in a recent meta-analysis. In total, 30–50 % of remitted patients present with residual symptoms by the
end of treatment. A common residual symptom is rumination, a process of recurrent negative thinking and
dwelling on negative affect. Rumination has been demonstrated as a major factor in vulnerability to depression,
predicting the onset, severity, and duration of future depression. Rumination-focused cognitive behavioural therapy
is a psychotherapeutic treatment targeting rumination. Because rumination plays a major role in the initiation and
maintenance of depression, targeting rumination with rumination-focused cognitive behavioural therapy may be
more effective in treating depression and reducing relapse than standard cognitive behavioural therapy.
Method/design: This study is a two-arm pragmatic randomised controlled superiority trial comparing the
effectiveness of group-based rumination-focused cognitive behaviour therapy with the effectiveness of group-based
cognitive behavioural therapy for treatment of depression. One hundred twenty-eight patients with depression will be
recruited from and given treatment in an outpatient service at a psychiatric hospital in Denmark. Our primary outcome
will be severity of depressive symptoms (Hamilton Rating Scale for Depression) at completion of treatment. Secondary
outcomes will be level of rumination, worry, anxiety, quality of life, behavioural activation, experimental measures of
cognitive flexibility, and emotional attentional bias. A 6-month follow-up is planned and will include the primary
outcome measure and assessment of relapse.
Discussion: The clinical outcome of this trial may guide clinicians to decide on the merits of including
rumination-focused cognitive behavioural therapy in the treatment of depression in outpatient services.
Trial registration: ClinicalTrials.gov Identifier: NCT02278224, registered 28 Oct. 2014.
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Cognitive behavioural therapy (CBT) is a recommended
treatment for unipolar depression, and a large number
of studies provide supportive evidence for its efficacy in
both an individual as well as a group format [1–3]. CBT
has been shown to be effective in the short term and to
have enduring effects in reducing the risk of returning
symptoms after treatment has ended. However, approxi-
mately one third of the patients do not respond satisfac-
torily to the treatment [4, 5], and post-treatment
residual symptoms are a common problem; as many as
30–50 % of remitted patients experience residual symp-
toms at the end of treatment [6]. Residual symptoms of
depression are associated with ongoing psychosocial and
functional disability and have been demonstrated to pre-
dict poorer long-term outcome of major depression, in-
cluding increased rates of relapse [7–9]. A recent meta-
analysis reports relapse rates of around 29 % within 1
year and 56 % within 2 years [10].
Recent studies have evaluated the potential benefit of
continuation-phase CBT in reducing residual symptoms
as well as in preventing subsequent depressive relapse or
recurrence. In general, continuation-phase cognitive
therapies have proven to be beneficial in reducing rates
of relapse and recurrence [10]. Yet, in most of these
studies, only a modest reduction in residual symptoms
was observable [11, 12], indicating the possibility of fur-
ther improvement in efficacy by targeting key residual
symptoms. With the aim of improving efficacy, an in-
creased focus has been directed toward a common re-
sidual symptom, namely depressive rumination [13, 14].
Rumination is a passive process of recurrent negative
thinking and dwelling on negative affect, causes, and
symptoms [15] and has been shown to be a major factor
in vulnerability to depression as well as predicting the
onset, severity, and duration of future depressive epi-
sodes [16, 17]. Consequently, if involved in the patho-
genesis of depression, rumination may constitute a
relevant target for psychological intervention. In support
of this, recent psychotherapeutic interventions designed
to target depressive rumination show promising results
[18–20]. The strongest evidence thus far exists for the
rumination-focused cognitive behavioural therapy
(RFCBT) developed by Watkins and colleagues [18].
RFCBT is based on a conceptualization of repetitive
thinking that differentiates between a functional and a
dysfunctional style of thinking. The helpful style is char-
acterized by being concrete and specific, whereas the un-
helpful style is abstract and evaluative and does not lead
to problem solving (rumination) [21]. In RFCBT, rumin-
ation is formulated as a habitual behaviour controlled by
the laws of behavioural psychology [22] and maintained
by negative reinforcement. Rumination can act as a form
of avoidance by thinking about difficulties rather thanconfronting them directly in the real world and thereby
avoiding the risk of failure and negative outcomes.
Hence, rumination can become reinforced by escape and
avoidance. Grounded in behavioural psychology and re-
search, RFCBT focuses on functional analyses of the tar-
get behaviour, rumination, and combines strategies from
behavioural activation with novel strategies to foster
concrete, process-focused, and specific thinking. RFCBT
differs from standard CBT by focusing on modifying the
process of thinking, whereas CBT focuses on modifying
the content of the thoughts and content of dysfunctional
schemas [14]. With only a handful of trials conducted,
the evidence for RFCBT is still sparse, although it is
promising. For example, in a recent clinical trial with pa-
tients with medication-refractory residual depression, 42
patients were randomly allocated (1:1) to treatment-as-
usual (TAU) consisting of continuation anti-depressants
and outpatient clinical management or to TAU plus up
to 12 sessions of individual RFCBT. RFCBT was found
to be superior to TAU; 62 % of patients in the RFCBT
treatment condition achieved remission, compared with
21 % in the TAU [18]. However, to date, no study has
made a direct comparison of RFCBT with standard
CBT. The aim of the present study is to compare group-
based rumination-focused cognitive behaviour therapy
(g-RFCBT) with group-based standard cognitive be-
havioural therapy (g-CBT) for depression on the ef-
fectiveness of treatment and the reduction of relapse
rates at 6-month follow-up.
Methods/design
This study is a two-arm pragmatic randomised con-
trolled trial comparing the effectiveness of g-RFCBT
with the effectiveness of g-CBT for treatment of depres-
sion. Our primary hypothesis is that g-RFCBT will be
superior to g-CBT in reducing depressive symptoms
measured on the score on the Hamilton Rating Scale for
Depression (HRSD) at the end of treatment. Our sec-
ondary hypothesis is that g-RFCBT will be superior to g-
CBT in reducing relapse at 6-month follow-up after the
end of treatment. Relapse is defined as a score of 13
points or more on the HRSD.
Eligibility criteria
Patients who are between 18 and 65 years of age and
who meet Diagnostic and Statistical Manual of Mental
Disorders, 4th Edition (DSM-IV) criteria for a current
episode of unipolar major depression or recurrent or
chronic depression in a structured M.I.N.I. 5.0 interview
and with a score of 13 or more on the 17-item HRSD
can be included [18]. Patients with psychotic symptoms,
bipolar disorder, functional illiteracy, or alcohol and drug
abuse will be excluded. Patients with depression and co-
morbid anxiety or personality disorder are included in
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Recruitment
The study takes place in a community psychiatric out-
patient service in Hillerød, Denmark, which treats 200–
250 patients with diagnosed depression per year. Pa-
tients who are referred for treatment with a primary
diagnosis of depression, recurrent or chronic, will be re-
cruited to the study. We plan to recruit a total of 128
patients, 64 in each treatment arm.
The psychiatrist conducting the initial evaluation of
the patients will invite the patients to talk to the re-
searcher if the inclusion criteria are met. Written in-
formed consent will be obtained from all patients prior
to enrolment in the study. The researcher will validate
the depression diagnosis and screen for DSM-IV Axis I
co-morbidity by using the structured International
Neuropsychiatric Interview M.I.N.I. version 5.0 [23] and
for DSM-IV Axis II disorders by using the Standard-
ized Assessment of Personality-Abbreviated Scale, an
eight-item semi-structured interview screening for the
presence of a personality disorder [24]. Patients meet-
ing the inclusion criteria will be included in the
study, and baseline assessment will be conducted
within 2 weeks prior to commencement of the psy-
chotherapeutic treatment. After the baseline assess-
ment, the patients are randomly assigned to receive
one of the two treatment options.
Randomisation and concealment
Participants will be allocated in a 1:1 ratio to either g-
CBT or g-RFCBT. The randomisation will be concealed
from the investigator by use of an off-site computer-
based randomisation. Patients are randomly assigned in
blocks of variable sizes (6–10) according to a pre-study
computer-generated (Microsoft Excel 2011; Microsoft
Corporation, Redmond, WA, USA) randomisation list to
receive one of the two treatment options.
All assessments will be conducted equally in both
treatment conditions by researchers blind to randomisa-
tion. To successfully maintain the blinding throughout
the trial, the researchers conducting the patient assess-
ments will be instructed to remind the patients of the
confidential nature of their treatment.
Interventions
RFCBT is a manualised CBT treatment [18] with 12 in-
dividual sessions scheduled weekly or fortnightly. In this
trial, the treatment will be adapted to a group format
consisting of one individual session of 1 h followed by
11 group sessions of 3 h (with two breaks of 15 min)
scheduled weekly or fortnightly. RFCBT is theoretically
informed by the distinction between constructive andunconstructive forms of repetitive thinking [21]. The
main purpose of the treatment is to coach individuals to
shift from unconstructive rumination to constructive
thinking and problem solving through the use of func-
tional analysis, experiential/imagery exercises, and be-
havioural experiments. For example, individuals will
practice shifting from a general, evaluative, and abstract
way of thinking to a more specific, descriptive, and con-
crete style of thinking. The g-RFCBT consists of an indi-
vidual session focusing on development of an
idiosyncratic RFCBT model of depression and finding
individual treatment goals followed by 11 group sessions.
Session 1 consists of psychoeducation about the connec-
tion between mood and behaviour and an introduction
of rumination as a maladaptive behaviour [22]. Sessions
2 and 3 consist of training in the use of functional ana-
lysis to identify maladaptive behaviours [25]. Session 4
consists of training in rational and stepwise problem
solving [26]. Session 5 consists of training in shifting
from a maladaptive abstract thinking style to a con-
structive and more specific thinking style [27]. Session 6
consists of training in being present and absorbed in ac-
tivities [28]. Sessions 7 and 6 consist of training in build-
ing compassionate images and in the use of compassion
in everyday life [29]. Session 9 consists of training how
to evaluate personal progress without getting stuck in
unconstructive thinking [28]. Session 10 consists of
working on how to engage in a valuable life and avoid
getting stuck in rumination. Session 11 consists of build-
ing resilience and psychoeducation on prevention of re-
lapse [14].
The control group intervention is CBT based on
Aaron Beck’s CBT manual for depression [27] but
adapted to group format consisting of one individual
session of 1 h followed by 11 group sessions of 3 h
scheduled weekly or fortnightly, matched in duration,
structure, and therapist contact with g-RFCBT.
In addition, all participants will be offered clinical
management and treatment with anti-depressant medi-
cation if needed, as evaluated by a highly trained and ex-
perienced psychiatrist at the outpatient service. There
are no restrictions in use of anti-depressant medication
in this trial, but use of anti-depressive medication and
changes in type of medication or dosage will be
registered.
Intervention fidelity
Therapists conducting the g-RFCBT and the g-CBT
therapies are trained cognitive behavioural therapists
with at least 7 years of experience with CBT. The thera-
pists conducting g-RFCBT groups are trained and super-
vised 1 h per month by the developer of RFCBT (ERW).
The therapists conducting the g-CBT groups are super-
vised 1 h per month by a highly trained and experienced
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sions discussed on Skype as well as face-to-face feedback
on recorded sessions.
Adherence to the clinical manuals as well as compe-
tency in conducting the therapy will be assessed by using
videotapes from therapy sessions. Experts in both treat-
ments will rate a random 10 % sample of videotapes,
stratified by therapy session and groups. Adherence to
the manuals will be rated by using a checklist to assess
the presence of key therapy components and the absence
of prohibited components for both treatments. Compe-
tence will be rated by using the Cognitive Therapy Rat-
ing Scale (CTRS) for g-CBT [30] and an adjusted
version of the CTRS for g-RFCBT. For both arms, kappa
statistics on inter-rater reliability will be reported.
Outcomes
Primary outcome
Primary outcome is the post-treatment assessment with
the HRSD [31]. The HRSD is a standardised clinical
interview developed to assess severity of depressive
symptoms. The researcher conducting the interviews is
trained in the procedure and blinded with regard to the
treatment group.
Secondary outcomes
Secondary outcomes will be conducted post-treatment
by using the following measures. The Hamilton Depres-
sion Rating Scale (HAM-D6) is a six-item self-report rat-
ing scale (corresponding to the 17-item observer-rated
HRSD), which measures the core symptoms of the de-
pression construct on a unipolar scale. The HAM-D6
questionnaire has been shown to be a reliable and valid
measure of the severity of depressive symptoms in a
clinical sample [32]. The Behavioural Activation for De-
pression Scale (BADS) is a 25-item questionnaire meas-
uring changes in avoidance and activation over the
course of behavioural activation and has been shown
to be reliable and valid in a community sample with
elevated depressive symptoms [33]. The Penn State
Worry Questionnaire (PSWQ) is a 16-item question-
naire assessing the general trait of worry and has
been shown to be reliable and valid in a clinical sam-
ple [34]. The Rumination Response Scale (RRS) is a
22-item self-report measure that assesses ruminative
response to depressive symptoms. Participants are
asked to indicate the frequency of rumination with
the total score indicating the severity of rumination
used as a strategy in response to depressive symptoms
[35]. The Generalised Anxiety Scale (GAD-7) is a
seven-item questionnaire assessing the severity of
symptoms of generalised anxiety disorder. GAD-7 has
been shown to be valid in a community sample [36]. The
World Health Organization Well Being Index (WHO-5) isa five-item questionnaire assessing the level of well-being
[37]. The Trail Making Task A and B is a neuropsycho-
logical test of visual attention and task switching. It con-
sists of two parts in which the test respondent is asked to
connect 25 dots as fast as possible while still maintaining
accuracy [38]. The Dot Probe Task is a non-verbal com-
puterized task assessing the level of visual attentional bias
from emotional pictures [39]. Furthermore, assessment
with Dot Probe Task, HAM-D6, RSS, PSWQ, and BADS
will take place after the fourth and the eighth sessions. A
6-month post-treatment follow-up will be conducted to
measure the level of depressive symptoms with HRSD,
and depressive relapse will be assessed by a diagnostic
interview based on DSM-IV criteria for depression.Adverse events
All adverse events will be monitored by the psychothera-
pists and the psychiatrists at the outpatient service and
reported in the patient case report. If a patient is at risk
of an adverse event, a psychotherapist, psychiatrist, or
research staff will take immediate action to prevent any
adverse event from happening. Use of anti-depressive
medication will be administered and monitored by expe-
rienced psychiatrists at the outpatient service. There are
no study-specific restrictions on change of dosage of or
types of anti-depressant medications. Medications, ad-
verse effects due to medication, and changes in medical
treatment will be reported in the patient case record by
the psychiatrists. We will compare the levels of usage of
anti-depressant medication and the reported adverse ef-
fects across the arms by conducting a screening of the
participants’ case reports when all participants have fin-
ished treatment.Statistical considerations
Sample size estimation
Assuming similar mean changes in HRSD scores from
pre- to post-intervention as found by Watkins and col-
leagues [18] for RFCBT (M = 7.81) and by Paykel and
colleagues [11] for CBT (M = 3.52) and a conservative
estimate of pooled standard deviation for change in
HRSD of 6 (when standard deviation = 3.60 for change in
HRSD in RFCBT), we estimate a between-treatment effect
size of Cohen’s d = 0.7. To detect a difference in effect size
of 0.7 between g-RFCBT and g-CBT at a two-tailed signifi-
cance level of 5 %, each treatment arm requires 44 patients
to obtain 90 % statistical power [40]. Assuming a dropout
rate of 20 %, we will recruit 55 patients into each treatment
arm. With an average size of the therapy group of m = 8 in
both treatment arms and an intraclass correlation of about
ρ = 0.05, a design effect of 1 + (m – 1)ρ = 1.35 follows, so
that we plan to recruit eight groups in each treatment arm
(128 patients in total).
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The primary outcome is the post-treatment score on
the HRSD, which is treated as a continuous, normally
distributed variable. The primary efficacy hypothesis
will be tested by using a multilevel two-group com-
parison (g-RFCBT versus g-CBT), with group as a
main effect, therapy group as a random intercept, and
the HRSD baseline score as a continuous covariate
[41]. The test will be performed at the 5 % two-tailed
significance level [42].
The primary test for efficacy will be based on the
intention-to-treat population with all randomised pa-
tients entering the analysis set. The multiple imput-
ation method will be used for missing data when
appropiate [42].
Ethical considerations
We will conduct the trial in such a way as to protect the
human rights and dignity of participants as reflected in
the Helsinki Declaration [43]. The patients will be in-
formed about the research project and purpose of the
project prior to participation and asked for informed
consent. No side effects due to the RFCBT have been re-
ported. It is not possible to pay the patients for partici-
pating in the research project. We will follow good
clinical practice in monitoring for suicide risk during all
research and clinical encounters with trial participants.
If any risk to participants due to expressed thoughts of
suicide is encountered, we will report these directly to
the psychiatrist responsible for treatment of the patient
(with the participant’s expressed permission), and if an
acute risk is present, we will arrange for an immediate
assessment by the psychiatrist responsible for the treat-
ment or follow the patient to the psychiatric emergency
room for further assessment of need of hospitalization.
The project has been approved by the Danish National
Ethical Scientific Committee (registration number H-1-
2013-049) and is registered at the Danish Data Protec-
tion Agency by the Mental Health Services of the Capital
Region of Denmark.
Discussion
Previous research supports rumination as a common re-
sidual symptom of depression that remains elevated after
both partial and full remission. Elevated rumination is
associated with diminished responsiveness to anti-
depressant medication and cognitive therapy [44, 45],
and rumination has been demonstrated as a crucial fac-
tor in vulnerability to depression, predicting the onset,
severity, and duration of future depression [16]. The pre-
liminary research on the effectiveness of RFCBT shows
promising results compared with TAU [18]; furthermore,
targeting rumination may improve relapse rates. In
addition, no trial has directly compared g-RFCBT withg-CBT, and this randomised study may provide the first
support for g-RFCBT as a potential alternative to g-CBT
treatment. This may be relevant for patients who have
not responded to CBT or for other reasons prefer a dif-
ferent, but still evidence-based, treatment for depression.
The group format of delivering therapy is more cost-
effective than individual therapy, which is widely used in
CBT treatment for depression in outpatient services in
Denmark. Service managers as well as the patients
would most likely welcome a cost-effective treatment for
depression with good outcome and reduced relapse
rates.
This trial is conducted in a naturalistic setting on a
heterogeneous sample of patients with recurrent depres-
sion, a single episode of depression, or chronic depres-
sion, and co-morbidity with anxiety and occasionally
with personality disorder. The results are highly general-
isable to the actual clinical reality in many outpatient
services in Denmark. The treatment that is being tested
in the present trial is robust as to heterogeneity and co-
morbidity and even has potential as a transdiagnostic
treatment for emotional disorders.
Trial status
Recruitment commenced in October 2013 and is ongoing.
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